Abstract： Objective To investigate the effect of Ziprasidone and Citalopram in the treatment of patients with firstepisode schizophrenia. Methods A total of 68 patients with first-episode schizophrenia who were treated at Xuzhou Guangci Hospital from January 2018 to January 2020 were selected and divided into the observation group and the control group according to a random number table, with 34 cases in each group. The control group were treated with Ziprasidone, and the observation group were provided with Ziprasidone combined with Citalopram. After 8 weeks of treatment, the treatment effect, executive function and eye movement function of the two groups were observed. Results There were no significant differences in the scores of the positive and negative syndrome scale (PANSS) and total score,eye movement function, or executive function between the two groups before treatment (P＞0.05). After 4 weeks of treatment, the negative symptoms score, psychopathology score and total score of the two groups were lower than before treatment, and the negative symptoms score, psychopathology score and total score of the observation group were lower than those of the control group, the differences were statistically significant (P＜0.05). After 8 weeks of treatment,PANSS scores and total score in both groups were lower than before and 4 weeks after treatment, and PANSS scores and total scores of the observation group were lower than those of the control group, the differences were statistically significant (P＜0.05). After 8 weeks of treatment, the number of eye fixation (NEF) and responsive search score (RSS)scores in the two groups were higher than those before treatment, and discriminant analysis (D) score was lower than that before treatment, the NEF and RSS scores of the observation group were higher than those of the control group,and the D score of the observation group was lower than that of the control group, with statistical significance (P＜0.05).After 8 weeks of treatment, the total number of tests, the number of continuous errors, and the number of random errors of the two group were lower than those before treatment, the number of correct responses and the number of completed classifications were higher than those before treatment and the total number of tests, the number of continuous errors,and the number of random errors in the observation group were lower than that in the control group, the number of correct responses and the number of classification completed in the observation group were higher than those in the control group, with statistical significances (P＜0.05). There was no statistically significant difference in adverse reactions between the two groups (P＜0.05). Conclusion Ziprasidone combined with Citalopram is effective in the treatment of patients with first-episode schizophrenia. It can significantly improve the PANSS score, the executive function and eye movement function of the patients, and has fewer adverse reactions, which can be widely used in clinical.
林雪飞. 齐拉西酮联合西酞普兰治疗首发精神分裂症患者的效果[J]. 中国当代医药, 2022, 29(4): 115-119.
LIN Xuefei. Effect of Ziprasidone combined with Citalopram in the treatment of patients with first-episode schizophrenia. 中国当代医药, 2022, 29(4): 115-119.
Meade N，Shi L，Meehan SR，et al.Efficacy and safety of brexpiprazole in patients with schizophrenia presenting with severe symptoms：Post-hoc analysis of short-and longterm studies[J].J Psychopharmacol，2020，34（8）：829-838.
Serrita J，Ralevski E，Yoon G，et al.A Pilot Randomized，Placebo-Controlled Trial of Glycine for Treatment of Schizophrenia and Alcohol Dependence[J].J Dual Diagn，2019，15（1）：46-55.
[20]
Simmons A，Carpenter-Conlin J，Bessonova L，et al.Qualitative Clinical Trial Exit Interviews Evaluating Treatment Benefit，Burden，and Satisfaction in Patients with Schizophrenia[J].CNS Spectr，2021，26（2）：156-157.
京公网安备 11010502046607号